SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

OMB APPROVAL

3235-0104 OMB Number:

Estimated average burden 0.5

hours per response:

SECURITIES F

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

| Filed pursuant to Section 16(a) of the Securities Exchange Act of 1 | 934 |
|---|-----|
| or Section 30(h) of the Investment Company Act of 1940 | |

| 1. Name and Address of Reporting Person [*] Samsara BioCapital GP, LLC | | Requiring (Month/Da | 2. Date of Event Requiring Statement (Month/Day/Year) 11/25/2024 | | 3. Issuer Name and Ticker or Trading Symbol <u>Neurogene Inc.</u> [NGNE] | | | | | | | |
|--|---------------------|------------------------|---|----------------|---|--|-------------|-----------------------|--|--|--|--|
| (Last) (First) (Middle) 628 MIDDLEFIELD ROAD | | | _ | | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director I 0% Owner | | | | 5. If Amendment, Date of Original Filed (Month/Day/Year)6. Individual or Joint/Group Filing | | |
| (Street) PALO ALTO | A | 94301 | | | | Officer (give title below) | Oth belo | er (specify w) | | Person | by One Reporting by More than One | |
| (City) (St | ate) | (Zip) | _ | | | | | | | | | |
| | | | able I - No | n-De | erivati | ive Securities Benefi | cially | Owned | | | | |
| 1. Title of Security (Instr. 4) | | | | | | | | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | | |
| Common Stock | | | | | | 1,668,357 | | Ι | By | Samsara Bic | Capital, L.P. ⁽¹⁾ | |
| | | (e. | | | | e Securities Benefici nts, options, conver | | | ;) | | | |
| 1. Title of Derivative Security (Instr. 4) 2. D Exp | | | 2. Date Exerc Expiration Da (Month/Day/) | cisable ate | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conve or Exe | rsion rcise | ise Form: | 6. Nature of Indirect Beneficial Ownership (Instr. | |
| | | Date Exercisable | | | or Nu of | | umber | | Direct (D) or Indirect (I) (Instr. 5) | 5) | | |
| Pre-Funded Wa | rrants (Righ | nt to Buy) | (2) | | (2) | Common Stock | 67,07 | 0 (3 |) | Ι | By Samsara BioCapital, L.P. | |
| Pre-Funded Warrants (Right to Buy) | | (2) | (2) | | Common Stock | 20,00 | 0 0.0 | 01 | Ι | By Samsara BioCapital, L.P. | | |
| 1. Name and Addro Samsara Bio | • | 0 | | | | | | | | | | |
| (Last) 628 MIDDLEF | (First) TELD ROA | - | liddle) | | | | | | | | | |
| (Street) PALO ALTO | СА | 94 | 4301 | | | | | | | | | |
| (City) | (State) | (Z | ip) | | | | | | | | | |
| 1. Name and Addro Samsara Bio | | - | | | | | | | | | | |
| (Last) (First) (Middle) 628 MIDDLEFIELD ROAD | | | | | | | | | | | | |
| (Street) PALO ALTO | СА | 94 | 1301 | | | | | | | | | |

| (City) | (State) | (Zip) |
|---------------------------------------|-----------------------|-----------------|
| 1. Name and Addre | ss of Reporting Perso | on [*] |
| (Last) C/O SAMSARA 628 MIDDLEFI | | (Middle) |
| (Street) PALO ALTO | СА | 94301 |
| (City) | (State) | (Zip) |

Explanation of Responses:

1. Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

2. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

3. The exercise price of the Pre-Funded Warrants is \$0.000001.

| <u>Samsara BioCapital GP,</u> <u>LLC, By /s/ Srinivas</u> <u>Akkaraju, Managing</u> <u>Member</u> | <u>11/27/2024</u> |
|---|---------------------------|
| Samsara BioCapital, L.P., By Samsara BioCapital GP, LLC, its General Partner, By/s/ Srinivas Akkaraju, Managing Member | <u>11/27/2024</u> |
| <u>/s/ Srinivas Akkaraju</u> ** Signature of Reporting Person | <u>11/27/2024</u> Date |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.